Oncolytics Biotech® Inc. announced the appointment of Andres A. Gutierrez, MD, PhD to the role of Chief Medical Officer. Most recently Dr. Gutierrez has held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc, Biomarin Pharmaceutical Inc, Proteolix, and Oculus Innovative Sciences. Alan Tuchman, MD, MBA, will remain with Oncolytics in his new role of Chief Neuro Oncology Research Officer.